Novo Nordisk has sold one of its early-stage autoimmune research programs to Bristol-Myers Squibb for an undisclosed amount.
As part of the agreement, Bristol-Myers obtains the exclusive rights to a discovery-stage biologics program that targets the innate immune system, which is the body’s first line of defense against infection. Novo’s program was striving to treat autoimmune disease by modulating bodily response to pathogens, correcting dysregulated immunity to steer patients back to health. The targets and diseases involved were not revealed.
Recently Novo Nordisk backed off research into inflammatory diseases, reconcentrating its efforts into diabetes and hemophilia, while redirecting some of its resources toward an obesity drug.
Source: Fierce Pharma